{"id":"intravitreal-anti-vegf-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain or discomfort"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Increased intraocular pressure"},{"rate":"0.05–0.1","effect":"Endophthalmitis"},{"rate":null,"effect":"Retinal detachment"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anti-VEGF agents bind to and neutralize VEGF, a key signaling protein that drives pathological neovascularization and vascular permeability in retinal diseases. By blocking VEGF, these injections reduce abnormal vessel formation, decrease retinal edema, and slow or halt vision loss in conditions characterized by excessive retinal angiogenesis.","oneSentence":"Intravitreal anti-VEGF injection blocks vascular endothelial growth factor to inhibit abnormal blood vessel growth in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:59.729Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular age-related macular degeneration (wet AMD)"},{"name":"Diabetic macular edema (DME)"},{"name":"Retinal vein occlusion (RVO)"},{"name":"Proliferative diabetic retinopathy (PDR)"}]},"trialDetails":[{"nctId":"NCT06890026","phase":"","title":"Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-15","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Treatment-naïve","enrollment":742},{"nctId":"NCT06893965","phase":"NA","title":"Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL","status":"RECRUITING","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2025-07-08","conditions":"Macular Diseases","enrollment":100},{"nctId":"NCT07481500","phase":"NA","title":"Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety","status":"NOT_YET_RECRUITING","sponsor":"Jakkrit Juhong","startDate":"2026-06","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":120},{"nctId":"NCT07438119","phase":"PHASE4","title":"Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients","status":"NOT_YET_RECRUITING","sponsor":"Kun Liu","startDate":"2026-03-15","conditions":"Diabetic Macular Edema (DME)","enrollment":114},{"nctId":"NCT07133438","phase":"PHASE4","title":"Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-08-01","conditions":"Retinal Vein Occlusion (RVO)","enrollment":120},{"nctId":"NCT04503551","phase":"PHASE3","title":"A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":"Diabetic Retinopathy","enrollment":174},{"nctId":"NCT07427719","phase":"","title":"Retinopathy of Prematurity - Visual Function and Retinal Structure","status":"NOT_YET_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2026-04-01","conditions":"Retinopathy of Prematurity (ROP), Prematurity Complications, Cerebral Visual Impairment","enrollment":140},{"nctId":"NCT04704921","phase":"PHASE2, PHASE3","title":"Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-12-29","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":630},{"nctId":"NCT07375901","phase":"NA","title":"the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"The Filatov Institute of Eye Diseases and Tissue Therapy","startDate":"2021-03-25","conditions":"AMD","enrollment":30},{"nctId":"NCT07338097","phase":"NA","title":"Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema","status":"ENROLLING_BY_INVITATION","sponsor":"CMH Multan Institute of Medical Sciences","startDate":"2025-09-07","conditions":"Diabetic Macular Edema (DME)","enrollment":116},{"nctId":"NCT05769153","phase":"PHASE1, PHASE2","title":"Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"RECRUITING","sponsor":"Alcon Research","startDate":"2023-12-06","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":140},{"nctId":"NCT07301775","phase":"PHASE4","title":"Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery","status":"NOT_YET_RECRUITING","sponsor":"Ahmad Zeeshan Jamil","startDate":"2026-01-01","conditions":"Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Cataract","enrollment":166},{"nctId":"NCT05666804","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-02-06","conditions":"Macular Polypoidal Choroidal Vasculopathy (PCV)","enrollment":148},{"nctId":"NCT03940690","phase":"PHASE3","title":"Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease","status":"TERMINATED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2019-10-24","conditions":"Retinal Telangiectasis, Coats Disease","enrollment":18},{"nctId":"NCT05802329","phase":"PHASE1","title":"Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)","status":"RECRUITING","sponsor":"Ocugen","startDate":"2024-01-13","conditions":"Center Involved Diabetic Macular Edema, Diabetic Macular Edema","enrollment":24},{"nctId":"NCT04101877","phase":"PHASE2","title":"The Sahlgrenska Anti-VEGF Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2020-09-03","conditions":"Neovascular Age-related Macular Degeneration","enrollment":402},{"nctId":"NCT06556368","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kodiak Sciences Inc","startDate":"2024-08-23","conditions":"Wet Age-related Macular Degeneration","enrollment":675},{"nctId":"NCT04777201","phase":"PHASE3","title":"A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-04-19","conditions":"Neovascular Age-related Macular Degeneration","enrollment":1036},{"nctId":"NCT04278417","phase":"PHASE3","title":"Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-11-19","conditions":"Proliferative Diabetic Retinopathy","enrollment":689},{"nctId":"NCT06491914","phase":"PHASE3","title":"A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-07-24","conditions":"Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema","enrollment":1118},{"nctId":"NCT04679935","phase":"PHASE4","title":"Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-13","conditions":"Age-related Macular Degeneration","enrollment":52},{"nctId":"NCT05407636","phase":"PHASE3","title":"Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":660},{"nctId":"NCT05542381","phase":"NA","title":"The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain","status":"COMPLETED","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2022-12-22","conditions":"Age-Related Macular Degeneration","enrollment":64},{"nctId":"NCT05456828","phase":"PHASE1","title":"A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"AskGene Pharma, Inc.","startDate":"2023-02-10","conditions":"Neovascular Age-related Macular Degeneration","enrollment":56},{"nctId":"NCT05940428","phase":"PHASE1","title":"A Study of ASKG712 in Patients With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"AskGene Pharma, Inc.","startDate":"2023-10-23","conditions":"Diabetic Macular Edema","enrollment":26},{"nctId":"NCT07144865","phase":"NA","title":"Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection","status":"COMPLETED","sponsor":"Bojie Hu","startDate":"2024-12-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":8},{"nctId":"NCT05536973","phase":"PHASE2","title":"Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2022-08-23","conditions":"Neovascular Age-related Macular Degeneration","enrollment":69},{"nctId":"NCT06011798","phase":"PHASE2","title":"Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)","status":"COMPLETED","sponsor":"Unity Biotechnology, Inc.","startDate":"2023-08-23","conditions":"Diabetic Macular Edema, Retinal Disease, Macular Edema","enrollment":52},{"nctId":"NCT06845163","phase":"PHASE2","title":"Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-02-08","conditions":"Diabetic Macular Edema, Center-involved Diabetic Macular Edema","enrollment":56},{"nctId":"NCT04420923","phase":"NA","title":"Optimizing the Treatment Strategy for Age-related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Olavs Hospital","startDate":"2020-05-20","conditions":"Wet Macular Degeneration","enrollment":250},{"nctId":"NCT07009574","phase":"","title":"The Treatment Burden of Myopic Choroidal Neovascularization","status":"NOT_YET_RECRUITING","sponsor":"Policlinico Gaspare Rodolico - San Marco Catania","startDate":"2025-06-01","conditions":"Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden","enrollment":100},{"nctId":"NCT06498050","phase":"PHASE4","title":"Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-07-10","conditions":"Diabetic Macular Edema","enrollment":52},{"nctId":"NCT07002372","phase":"NA","title":"Effect of Video Viewing on Intravitreal Injection Experience","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-05-05","conditions":"Age Related Macular Degeneration, Diabetic Retinopathy, Choroidal Neovascularization","enrollment":182},{"nctId":"NCT05604989","phase":"PHASE3","title":"Associations Between the Oral and Intestinal Microbiome and Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2023-01-01","conditions":"Neovascular Age-related Macular Degeneration","enrollment":45},{"nctId":"NCT04774926","phase":"PHASE4","title":"Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-15","conditions":"Neovascular Age-related Macular Degeneration","enrollment":122},{"nctId":"NCT06951087","phase":"PHASE3","title":"Intravitreal and Intracameral DEX in NPDR","status":"ENROLLING_BY_INVITATION","sponsor":"Affiliated Hospital of Nantong University","startDate":"2022-01-31","conditions":"Non-Proliferative Diabetic Retinopathy","enrollment":80},{"nctId":"NCT06929507","phase":"NA","title":"Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients","status":"RECRUITING","sponsor":"University Hospital, Alexandroupolis","startDate":"2025-03-10","conditions":"Renal Function Disorder, Diabetic Macular Edema (DME), Neovascular Age Related Macular Degeneration","enrollment":60},{"nctId":"NCT06902207","phase":"","title":"Real-world Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-10","conditions":"Intraocular Inflammation","enrollment":6053},{"nctId":"NCT06270836","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kodiak Sciences Inc","startDate":"2024-05-01","conditions":"Diabetic Retinopathy","enrollment":255},{"nctId":"NCT03585556","phase":"PHASE1","title":"AAVCAGsCD59 for the Treatment of Wet AMD","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-09-13","conditions":"Wet Age-related Macular Degeneration","enrollment":25},{"nctId":"NCT06511700","phase":"","title":"Implementation of the Intravitreal Injection Administered by Nurses","status":"ENROLLING_BY_INVITATION","sponsor":"Corporacion Parc Tauli","startDate":"2025-01-15","conditions":"Macular Edema, Macular Degeneration, Diabetic Macular Edema","enrollment":200},{"nctId":"NCT05003245","phase":"PHASE3","title":"Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-11-01","conditions":"Age Related Macular Degeneration","enrollment":407},{"nctId":"NCT03172299","phase":"PHASE3","title":"Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2017-06-08","conditions":"Ocular Melanoma","enrollment":57},{"nctId":"NCT06878573","phase":"","title":"Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema","status":"COMPLETED","sponsor":"Augenabteilung Allgemeines Krankenhaus Linz","startDate":"2023-11-22","conditions":"Age Related Macular Degeneration, Diabetic Macular Edema","enrollment":36},{"nctId":"NCT05571267","phase":"PHASE2","title":"Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD","status":"TERMINATED","sponsor":"IVERIC bio, Inc.","startDate":"2016-10-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1},{"nctId":"NCT05976139","phase":"NA","title":"Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies","status":"RECRUITING","sponsor":"Fondazione G.B. Bietti, IRCCS","startDate":"2023-09-06","conditions":"Macular Edema, Inherited Retinal Dystrophy, Laser Retinopathy","enrollment":10},{"nctId":"NCT06846073","phase":"NA","title":"Early Combined Use of Dexamethasone Intravitreal Implant and Anti-VEGF in the Treatment of DME.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-07-30","conditions":"Diabetic Macular Edema (DME)","enrollment":70},{"nctId":"NCT06841250","phase":"","title":"Early Changes in OCT Biomarkers After the First Intravitreal Anti-VEGF Injection in Treatment-naïve DME","status":"ENROLLING_BY_INVITATION","sponsor":"Sohag University","startDate":"2025-01-16","conditions":"Early OCT Biomarker Changes in Response to Anti-VEGF","enrollment":50},{"nctId":"NCT05640895","phase":"","title":"Intravitreal Injection Site and Perceived Pain","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2022-11-14","conditions":"Pain","enrollment":53},{"nctId":"NCT06610747","phase":"NA","title":"Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT","status":"RECRUITING","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2024-10-28","conditions":"Diabetic Macular Edema","enrollment":308},{"nctId":"NCT05003258","phase":"NA","title":"Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients with Resistant Macular Edema Secondary to Retinal Vein Occlusion After Intravitreal Anti-VEGF Injection","status":"COMPLETED","sponsor":"Assiut University","startDate":"2021-10-07","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":25},{"nctId":"NCT06771271","phase":"PHASE1","title":"A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-07-22","conditions":"Diabetic Macular Edema, Uveitic Macular Edema","enrollment":85},{"nctId":"NCT05610319","phase":"PHASE4","title":"Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"McMaster University","startDate":"2023-05-01","conditions":"Diabetic Macular Edema","enrollment":446},{"nctId":"NCT04740671","phase":"PHASE3","title":"A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-07-01","conditions":"Age Related Macular Degeneration","enrollment":410},{"nctId":"NCT06710951","phase":"NA","title":"Effect of Povidone-iodine 5% Vs 1% on the Ocular Surface in Intravitreal Injections of Anti-VEGF","status":"COMPLETED","sponsor":"José Gerardo García Aguirre","startDate":"2021-11-15","conditions":"Dry Eye","enrollment":88},{"nctId":"NCT02387957","phase":"PHASE2","title":"A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2016-04-26","conditions":"Age-Related Macular Degeneration","enrollment":63},{"nctId":"NCT05473715","phase":"PHASE4","title":"A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment","status":"TERMINATED","sponsor":"Bayer","startDate":"2023-04-25","conditions":"Neovascular (Wet) Age-related Macular Degeneration","enrollment":3},{"nctId":"NCT04239027","phase":"PHASE3","title":"A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-01-26","conditions":"Neovascular Age Related Macular Degeneration","enrollment":210},{"nctId":"NCT04597632","phase":"PHASE3","title":"An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-12-16","conditions":"Neovascular Age-related Macular Degeneration","enrollment":248},{"nctId":"NCT05066230","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)","status":"TERMINATED","sponsor":"Kodiak Sciences Inc","startDate":"2021-09-07","conditions":"Non-proliferative Diabetic Retinopathy","enrollment":253},{"nctId":"NCT06572553","phase":"PHASE2, PHASE3","title":"Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-03-01","conditions":"Age-Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":30},{"nctId":"NCT04603937","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)","status":"TERMINATED","sponsor":"Kodiak Sciences Inc","startDate":"2020-09-30","conditions":"Diabetic Macular Edema","enrollment":459},{"nctId":"NCT04611152","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)","status":"TERMINATED","sponsor":"Kodiak Sciences Inc","startDate":"2020-09-30","conditions":"Diabetic Macular Edema","enrollment":460},{"nctId":"NCT04469595","phase":"PHASE4","title":"A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimera Sciences","startDate":"2020-08-31","conditions":"Diabetic Macular Edema","enrollment":300},{"nctId":"NCT06391411","phase":"NA","title":"Effect of Micronutrient Supplementation on the Intestinal Microbiota in Patients With Age-related Macular Degeneration - The Gut-Retina-axis Study","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2021-03-01","conditions":"Age-Related Macular Degeneration","enrollment":45},{"nctId":"NCT04049266","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.","status":"TERMINATED","sponsor":"Kodiak Sciences Inc","startDate":"2019-10-08","conditions":"Wet Macular Degeneration","enrollment":559},{"nctId":"NCT03630315","phase":"PHASE1","title":"CLN-0046: Treatment of AMD Subjects With OTX-TKI","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2019-02-18","conditions":"Neovascular Age-related Macular Degeneration","enrollment":29},{"nctId":"NCT04964089","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)","status":"COMPLETED","sponsor":"Kodiak Sciences Inc","startDate":"2021-06-23","conditions":"Wet Age-related Macular Degeneration","enrollment":557},{"nctId":"NCT06272565","phase":"","title":"Exploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage","status":"NOT_YET_RECRUITING","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2024-07-03","conditions":"Diabetic Retinopathy, Diabetic Macular Edema, Anti-vascular Endothelial Growth Factor","enrollment":240},{"nctId":"NCT04592419","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)","status":"COMPLETED","sponsor":"Kodiak Sciences Inc","startDate":"2020-09-25","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":568},{"nctId":"NCT04411693","phase":"PHASE4","title":"Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2020-04-10","conditions":"Diabetic Macular Edema","enrollment":23},{"nctId":"NCT00417716","phase":"PHASE3","title":"Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2005-09","conditions":"Diabetes Mellitus Type 2, Diabetic Macular Edema","enrollment":""},{"nctId":"NCT06351033","phase":"","title":"Ozonized Oil as Dietary Supplement in Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alba Di Pardo","startDate":"2023-10-31","conditions":"Maculopathy","enrollment":60},{"nctId":"NCT04075136","phase":"PHASE4","title":"Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2023-03-30","conditions":"Exudative Age Related Macular Degeneration","enrollment":""},{"nctId":"NCT06317922","phase":"NA","title":"Evaluation of Dry Eye Disease's Signs in Patients Who Were Administered Intravitreal Anti-VEGF Injections","status":"RECRUITING","sponsor":"Francesco Bandello","startDate":"2024-02-05","conditions":"Dry Eye Syndromes","enrollment":60},{"nctId":"NCT05728476","phase":"NA","title":"Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema","status":"RECRUITING","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2024-03-05","conditions":"Diabetic Macular Edema, Pars Plana Vitrectomy, Conbercept","enrollment":102},{"nctId":"NCT06243406","phase":"","title":"Study on the Biomarkers of Anti-VEGF Treatment for Choroidal Neovascularization","status":"UNKNOWN","sponsor":"Beijing Hospital","startDate":"2024-02-10","conditions":"Choroidal Neovascularization","enrollment":80},{"nctId":"NCT04674254","phase":"PHASE4","title":"Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-03-30","conditions":"Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression, Diabetic Retinopathy","enrollment":43},{"nctId":"NCT05126966","phase":"PHASE3","title":"A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2023-12-29","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":""},{"nctId":"NCT06205979","phase":"EARLY_PHASE1","title":"Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-12-12","conditions":"Diabetic Macular Edema","enrollment":50},{"nctId":"NCT02924311","phase":"","title":"Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-09-21","conditions":"Diabetic Retinopathy","enrollment":402},{"nctId":"NCT02279537","phase":"","title":"Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-01-02","conditions":"Wet Macular Degeneration","enrollment":593},{"nctId":"NCT05324150","phase":"","title":"M Charts Versus Amsler Test in Evaluating Metamorphopsia in nAMD","status":"COMPLETED","sponsor":"Ospedale Santa Croce-Carle Cuneo","startDate":"2022-05-09","conditions":"Macular Degeneration, Wet, Metamorphopsia","enrollment":57},{"nctId":"NCT04993352","phase":"PHASE1, PHASE2","title":"Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-07-15","conditions":"Age Related Macular Degeneration","enrollment":20},{"nctId":"NCT04140448","phase":"","title":"Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"Renmin Hospital of Wuhan University","startDate":"2023-10-09","conditions":"Retinal Vein Occlusion, Macular Edema","enrollment":60},{"nctId":"NCT03784443","phase":"PHASE2, PHASE3","title":"Combined Ranibizumab and Iluvien for Diabetic Macular Oedema","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2019-09-01","conditions":"Diabetic Macular Edema, Diabetes","enrollment":""},{"nctId":"NCT04626128","phase":"PHASE1, PHASE2","title":"Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD","status":"COMPLETED","sponsor":"Clearside Biomedical, Inc.","startDate":"2020-12-15","conditions":"Neovascular Age-related Macular Degeneration","enrollment":27},{"nctId":"NCT01549132","phase":"","title":"Retinal Oximtery Following Treatment for Diabetic Maculopathy","status":"COMPLETED","sponsor":"East Kent Hospitals University NHS Foundation Trust","startDate":"2012-04","conditions":"Diabetic Maculopathy","enrollment":45},{"nctId":"NCT05156021","phase":"NA","title":"A Study on the Treatment Strategy of NVG Secondary to PDR","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2021-12-12","conditions":"Neovascular Glaucoma, Proliferative Diabetic Retinopathy","enrollment":39},{"nctId":"NCT05138029","phase":"PHASE3","title":"Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2021-11-15","conditions":"Diabetic Retinopathy","enrollment":60},{"nctId":"NCT03714308","phase":"","title":"Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-01-28","conditions":"Macular Degeneration","enrollment":554},{"nctId":"NCT02634333","phase":"PHASE3","title":"Anti-VEGF Treatment for Prevention of PDR/DME","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2016-01","conditions":"Diabetic Retinopathy, Diabetic Macular Edema","enrollment":399},{"nctId":"NCT02623023","phase":"NA","title":"Prophylaxis for Anti-VEGF-induced IOP Elevation","status":"WITHDRAWN","sponsor":"McMaster University","startDate":"2019-01-01","conditions":"Ocular Hypertension","enrollment":""},{"nctId":"NCT05144282","phase":"","title":"The Analysis of Association of Retinopathy of Prematurity, Gut Microbiome Profile, and Systemic Inflammation","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2020-08-15","conditions":"Retinopathy of Prematurity, Microbiome","enrollment":240},{"nctId":"NCT05132257","phase":"","title":"Genetic Polymorphism and Retinopathy of Prematurity: Correlation of Clinical Presentations and Severity","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-04-12","conditions":"Retinopathy of Prematurity, Genetic Polymorphism","enrollment":500},{"nctId":"NCT00606138","phase":"PHASE1, PHASE2","title":"Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2008-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":9},{"nctId":"NCT03971162","phase":"NA","title":"Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization","status":"COMPLETED","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2019-06-13","conditions":"Myopic Choroidal Neovascularisation","enrollment":50},{"nctId":"NCT05759884","phase":"NA","title":"Efficacy Analysis of Anti-VEGF Drugs Combined With Micropulse Laser in the Treatment of Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-02-01","conditions":"Macular Edema Due to Type 2 Diabetes Mellitus","enrollment":40},{"nctId":"NCT04563299","phase":"PHASE4","title":"Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections","status":"TERMINATED","sponsor":"Retina Vitreous Associates of Florida","startDate":"2020-12-09","conditions":"Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":10},{"nctId":"NCT04991350","phase":"PHASE4","title":"Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema","status":"TERMINATED","sponsor":"Cairo University","startDate":"2021-11-26","conditions":"Diabetic Macular Edema, Macular Ischemia, Diabetic Retinopathy","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":189,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ranibizumab, bevacizumab, or aflibercept","Bevacizumab (Avastin)","Ranibizumab (Lucentis)","Aflibercept (Eylea)"],"phase":"marketed","status":"active","brandName":"intravitreal Anti-VEGF injection","genericName":"intravitreal Anti-VEGF injection","companyName":"Seoul National University Bundang Hospital","companyId":"seoul-national-university-bundang-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intravitreal anti-VEGF injection blocks vascular endothelial growth factor to inhibit abnormal blood vessel growth in the eye. Used for Neovascular age-related macular degeneration (wet AMD), Diabetic macular edema (DME), Retinal vein occlusion (RVO).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}